Positive News SentimentPositive NewsNASDAQ:ESLA Estrella Immunopharma (ESLA) Stock Price, News & Analysis $0.72 0.00 (-0.19%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$0.74 +0.02 (+2.18%) As of 08/14/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Estrella Immunopharma Stock (NASDAQ:ESLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Estrella Immunopharma alerts:Sign Up Key Stats Today's Range$0.72▼$0.7450-Day Range$0.70▼$1.1552-Week Range$0.68▼$3.15Volume9,010 shsAverage Volume39,046 shsMarket Capitalization$31.12 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California. Read More Estrella Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreESLA MarketRank™: Estrella Immunopharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 536th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEstrella Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialEstrella Immunopharma has a consensus price target of $8.00, representing about 1,006.2% upside from its current price of $0.72.Amount of Analyst CoverageEstrella Immunopharma has only been the subject of 1 research reports in the past 90 days.Read more about Estrella Immunopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Estrella Immunopharma are expected to decrease in the coming year, from ($0.29) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Estrella Immunopharma is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Estrella Immunopharma is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Estrella Immunopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.12% of the float of Estrella Immunopharma has been sold short.Short Interest Ratio / Days to CoverEstrella Immunopharma has a short interest ratio ("days to cover") of 1.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Estrella Immunopharma has recently decreased by 11.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEstrella Immunopharma does not currently pay a dividend.Dividend GrowthEstrella Immunopharma does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment1.62 News SentimentEstrella Immunopharma has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Estrella Immunopharma this week, compared to 1 article on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of Estrella Immunopharma is held by insiders.Percentage Held by Institutions0.35% of the stock of Estrella Immunopharma is held by institutions.Read more about Estrella Immunopharma's insider trading history. Receive ESLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESLA Stock News HeadlinesEstrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaAugust 11, 2026 | finance.yahoo.comEstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJuly 29, 2026 | finance.yahoo.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s LymphomaJuly 24, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's LymphomaJuly 24, 2026 | businesswire.comESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?July 14, 2026 | finance.yahoo.comEstrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board MemberJuly 7, 2026 | businesswire.comEstrella Immunopharma Shareholders Ratify 2026 Auditor AppointmentJune 30, 2026 | tipranks.comSee More Headlines ESLA Stock Analysis - Frequently Asked Questions How have ESLA shares performed this year? Estrella Immunopharma's stock was trading at $1.56 on January 1st, 2026. Since then, ESLA stock has decreased by 53.6% and is now trading at $0.7232. How were Estrella Immunopharma's earnings last quarter? Estrella Immunopharma, Inc. (NASDAQ:ESLA) released its earnings results on Thursday, August, 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.04. Who are Estrella Immunopharma's major shareholders? Top institutional shareholders of Estrella Immunopharma include BlackRock Inc. (0.12%). View institutional ownership trends. How do I buy shares of Estrella Immunopharma? Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Estrella Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Estrella Immunopharma investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Children's Place (PLCE). Company Calendar Last Earnings8/13/2026Today8/14/2026Next Earnings (Estimated)9/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ESLA's financial health is in the Yellow zone, according to TradeSmith. ESLA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ESLA CIK1844417 Webwww.estrellabio.com Phone510-318-9098FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Estrella Immunopharma$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+1,006.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.06 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-289.98% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-2.68Miscellaneous Outstanding Shares43,034,000Free Float40,538,000Market Cap$31.12 million OptionableNot Optionable Beta0.88 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ESLA) was last updated on 8/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
